|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
RS67077B1
(sr)
|
2009-05-02 |
2025-08-29 |
Genzyme Corp |
Genska terapija za neurodegenerativne poremećaje
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
EP3514232A1
(en)
|
2010-04-23 |
2019-07-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
JP2013533847A
(ja)
|
2010-04-23 |
2013-08-29 |
ユニバーシティ オブ マサチューセッツ |
コレステロール関連障害のａａｖベースの治療
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
RS66184B1
(sr)
|
2011-04-22 |
2024-12-31 |
Univ California |
Adeno-povezani virioni virusa sa varijantama kapsida i postupci za njihovu primenu
|
|
RU2692251C2
(ru)
|
2013-05-15 |
2019-06-24 |
Риджентс Оф Зэ Юниверсити Оф Миннесота |
Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
|
|
ES2897508T3
(es)
|
2013-05-31 |
2022-03-01 |
Univ California |
Variantes de virus adenoasociados y métodos de uso de las mismas
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
KR102288849B1
(ko)
|
2014-03-17 |
2021-08-12 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
DK3119797T3
(da)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
EP4600255A3
(en)
|
2014-05-02 |
2025-10-22 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
|
MX383227B
(es)
*
|
2014-05-14 |
2025-03-13 |
UNIV AUTòNOMA DE BARCELONA |
Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
US10450563B2
(en)
|
2015-02-10 |
2019-10-22 |
Genzyme Corporation |
Variant RNAi
|
|
AU2016219398A1
(en)
|
2015-02-10 |
2017-09-28 |
Genzyme Corporation |
Enhanced delivery of viral particles to the striatum and cortex
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
KR20170137730A
(ko)
|
2015-03-02 |
2017-12-13 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
|
|
EP3719134B1
(en)
|
2015-03-11 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Rp2 vectors for treating x-linked retinitis pigmentosa
|
|
EP3277819B1
(en)
|
2015-03-24 |
2021-03-03 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
RS61907B1
(sr)
|
2015-04-06 |
2021-06-30 |
Subdomain Llc |
Polipeptidi koji sadrže de novo vezujući domen i njihova primena
|
|
US20180104289A1
(en)
|
2015-04-08 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
CA3002982A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
MX2018007330A
(es)
*
|
2015-12-15 |
2019-03-14 |
Genzyme Corp |
Vectores virales adeno-asociados para tratar mucolipidosis de tipo ii.
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US20190071681A1
(en)
*
|
2016-02-26 |
2019-03-07 |
University Of Florida Research Foundation, Incorporated |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
AU2017268382B2
(en)
*
|
2016-05-18 |
2023-09-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
EP3481958A4
(en)
*
|
2016-07-08 |
2019-12-25 |
The Trustees of The University of Pennsylvania |
METHOD AND COMPOSITIONS FOR TREATING DISTURBANCES AND DISEASES WITH RDH12
|
|
WO2018011572A1
(en)
*
|
2016-07-12 |
2018-01-18 |
The University Of Manchester |
Gene therapy
|
|
JP7071332B2
(ja)
|
2016-07-29 |
2022-05-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
変異カプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
|
|
BR112019002904A2
(pt)
*
|
2016-08-16 |
2019-06-25 |
The University Of North Carolina At Chapel Hill |
métodos e composições para transferência gênica direcionada
|
|
IL264872B2
(en)
*
|
2016-08-18 |
2025-02-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
WO2018035457A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Calimmune, Inc. |
Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
|
|
KR102759317B1
(ko)
|
2016-08-19 |
2025-01-31 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
재조합 자기-상보적인 아데노-부속 바이러스를 이용한 병태의 치료 방법 및 조성물
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190057110A
(ko)
|
2016-09-28 |
2019-05-27 |
코바, 인크. |
치료적 mots-c 관련 펩타이드
|
|
US11078238B2
(en)
|
2016-09-29 |
2021-08-03 |
University Of Florida Research Foundation, Incorporated |
AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
US11192925B2
(en)
|
2016-10-19 |
2021-12-07 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
MX2019006614A
(es)
|
2016-12-07 |
2019-10-15 |
Univ Florida |
Adnc del antagonista del receptor de interleucina-1.
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
US10898585B2
(en)
|
2017-04-14 |
2021-01-26 |
Ptc Therapeutics .Inc. |
Gene therapy for AADC deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
WO2018204803A1
(en)
*
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
JP7327803B2
(ja)
|
2017-05-09 |
2023-08-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症（ａｌｓ）を処置する方法
|
|
JP7330899B2
(ja)
|
2017-05-10 |
2023-08-22 |
マサチューセッツ アイ アンド イヤー インファーマリー |
ウイルスのアセンブリ活性化タンパク質（ａａｐ）依存性を改変する方法および組成物
|
|
CN110997693A
(zh)
|
2017-06-07 |
2020-04-10 |
阿德克斯公司 |
τ聚集抑制剂
|
|
US20200121746A1
(en)
|
2017-06-30 |
2020-04-23 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
EP3662060A2
(en)
*
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US11680249B2
(en)
|
2017-08-28 |
2023-06-20 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
US20200377887A1
(en)
*
|
2017-09-22 |
2020-12-03 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
EP3684932A1
(en)
|
2017-09-22 |
2020-07-29 |
Genzyme Corporation |
Variant rnai
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
CN111601884A
(zh)
*
|
2017-10-16 |
2020-08-28 |
维格内罗有限责任公司 |
Aav载体
|
|
WO2019077159A1
(en)
*
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS OF EXPRESSING POLYNUCLEOTIDE OF INTEREST IN CONE PHOTORECCEPTORS OF A SUBJECT COMPRISING SUB-RETINAL ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A RECOMBINANT AAV9 DERIVATIVE VECTOR
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
AU2018368431B2
(en)
|
2017-11-14 |
2024-03-21 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
CR20200210A
(es)
*
|
2017-11-15 |
2020-09-23 |
Friedrich Miescher Institute For Biomedical Res |
Promotor especìfico de las cèlulas del epitelio pigmentario retinal en primates
|
|
AU2018367606B2
(en)
*
|
2017-11-15 |
2024-08-29 |
The Regents Of The University Of Michigan |
Viral vectors comprising RDH12 coding regions and methods of treating retinal dystrophies
|
|
US20190153440A1
(en)
|
2017-11-21 |
2019-05-23 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
US20210017509A1
(en)
*
|
2018-03-23 |
2021-01-21 |
The Trustees Of Columbia University In The City Of New York |
Gene Editing for Autosomal Dominant Diseases
|
|
WO2019195449A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
EP3773743A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
BR112020021903A2
(pt)
|
2018-04-27 |
2021-03-02 |
Rocket Pharmaceuticals, Ltd. |
terapia genética para degeneração do snc
|
|
MX2020012077A
(es)
|
2018-05-15 |
2021-03-09 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
EP3813845A4
(en)
|
2018-05-15 |
2022-10-26 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
JP7563694B2
(ja)
*
|
2018-06-01 |
2024-10-08 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． |
優性網膜色素変性症の処置のための組成物および方法
|
|
EP3802829A4
(en)
|
2018-06-08 |
2022-10-19 |
University of Massachusetts |
ANTISENSE OLIGONUCLEOTIDES TO RESTORE DYSFERLIN PROTEIN EXPRESSION IN CELLS FROM PATIENTS WITH DYSFERLINOPATHY
|
|
PH12021550254A1
(en)
|
2018-08-03 |
2023-02-06 |
Genzyme Corp |
Variant rnai against alpha-synuclein
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
KR20210084459A
(ko)
|
2018-09-26 |
2021-07-07 |
캘리포니아 인스티튜트 오브 테크놀로지 |
표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020077091A1
(en)
*
|
2018-10-10 |
2020-04-16 |
Wisconsin Alumni Research Foundation |
Kir 7.1 gene therapy vectors and methods of using the same
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3863662A1
(en)
*
|
2018-10-12 |
2021-08-18 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020099956A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Indian Institute Of Technology Kanpur |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
CA3120923A1
(en)
*
|
2018-11-26 |
2020-06-04 |
Universitat Autonoma De Barcelona |
Fibroblast growth factor 21 (fgf21) gene therapy
|
|
JP7558167B2
(ja)
|
2018-12-03 |
2024-09-30 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
オリゴベンズアミド類似体およびがん処置におけるそれらの使用
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
WO2020142653A1
(en)
*
|
2019-01-04 |
2020-07-09 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy constructs for treating wilson disease
|
|
CN113631225A
(zh)
|
2019-01-18 |
2021-11-09 |
沃雅戈治疗公司 |
用于生产aav颗粒的方法和系统
|
|
CA3125294A1
(en)
*
|
2019-01-23 |
2020-07-30 |
University Of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
CN113518784A
(zh)
|
2019-01-28 |
2021-10-19 |
科巴公司 |
治疗性肽
|
|
FI3850089T3
(fi)
|
2019-02-04 |
2024-02-14 |
Freeline Therapeutics Ltd |
Polynukleotidejä
|
|
US20200297869A1
(en)
*
|
2019-03-04 |
2020-09-24 |
Adverum Biotechnologies, Inc. |
Sequential intravitreal administration of aav gene therapy to contralateral eyes
|
|
JP7549360B2
(ja)
*
|
2019-03-04 |
2024-09-11 |
デューク ユニバーシティ |
網膜症の診断および処置のための組成物および方法
|
|
WO2020182722A1
(en)
*
|
2019-03-08 |
2020-09-17 |
Universite Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
WO2020210713A1
(en)
*
|
2019-04-10 |
2020-10-15 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US12491263B2
(en)
|
2019-05-13 |
2025-12-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
KR20220009427A
(ko)
*
|
2019-05-17 |
2022-01-24 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
글리코시드 가수분해효소를 사용하는 망막 세포에 대한 유전자 치료 벡터의 개선된 전달
|
|
MX2021015076A
(es)
*
|
2019-06-10 |
2022-06-02 |
Homology Medicines Inc |
Composiciones de virus adeno-asociados para transferencia del gen de la enzima lisosomal arilsulfatasa-a (arsa) y metodos de uso de las mismas.
|
|
WO2020264438A2
(en)
|
2019-06-27 |
2020-12-30 |
University Of Florida Research Foundation, Incorporated |
Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
HRP20241647T1
(hr)
*
|
2019-07-15 |
2025-02-14 |
Meiragtx Uk Ii Limited |
Modificirani proteini aav kapsida za liječenje artritične bolesti
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
WO2021041324A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Duke University |
Compositions and methods for the treatment of pathological pain and itch
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
EP4025258A4
(en)
*
|
2019-09-03 |
2023-09-06 |
University of Cincinnati |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
|
|
JP2022551487A
(ja)
*
|
2019-10-10 |
2022-12-09 |
ソリッド・バイオサイエンシーズ・インコーポレーテッド |
改変されたａａｖカプシドおよびその使用
|
|
TW202128736A
(zh)
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療ｃ型尼曼—匹克病之腺相關病毒載體
|
|
CA3155154A1
(en)
*
|
2019-10-23 |
2021-04-29 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20220396808A1
(en)
*
|
2019-11-08 |
2022-12-15 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
AU2021213786A1
(en)
|
2020-01-29 |
2022-09-22 |
Genzyme Corporation |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
|
KR20220150906A
(ko)
*
|
2020-02-07 |
2022-11-11 |
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 |
신경변성의 발병 지연 또는 치료를 위한 대사체의 재프로그래밍
|
|
JP2023515795A
(ja)
*
|
2020-02-18 |
2023-04-14 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
Ａａｖカプシド－プロモーター相互作用および細胞選択的遺伝子発現
|
|
EP4110913A4
(en)
*
|
2020-02-28 |
2024-07-24 |
University of Massachusetts |
OLIGONUCLEOTIDES FOR PRNP MODULATION
|
|
CN115379834A
(zh)
*
|
2020-03-11 |
2022-11-22 |
马萨诸塞眼科耳科诊所 |
用于nmnat1相关视网膜变性的基因疗法
|
|
US20230138766A1
(en)
*
|
2020-03-31 |
2023-05-04 |
University Of Massachusetts |
Aav capsids variants and uses thereof
|
|
WO2021209521A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Genethon |
Vectors for the treatment of acid ceramidase deficiency
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
|
US20230203102A1
(en)
|
2020-05-13 |
2023-06-29 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023529503A
(ja)
*
|
2020-06-13 |
2023-07-10 |
オクロジェネクス インコーポレイテッド |
網膜症のためのａａｖ媒介性遺伝子導入
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
CA3190309A1
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001336A2
(pt)
|
2020-08-05 |
2023-02-14 |
Spacecraft Seven Llc |
Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
|
|
CN116194154A
(zh)
|
2020-08-07 |
2023-05-30 |
太空飞船七有限责任公司 |
使用aav载体的plakophilin-2(pkp2)基因疗法
|
|
TW202227632A
(zh)
|
2020-08-19 |
2022-07-16 |
美商史崔德生物公司 |
用於治療雷特症候群之腺相關病毒載體
|
|
US20230330267A1
(en)
*
|
2020-09-04 |
2023-10-19 |
Ohio State Innovation Foundation |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
WO2022087238A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
WO2022178410A1
(en)
*
|
2021-02-22 |
2022-08-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Viral vector-based gene therapy for ocular conditions
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
EP4329824A4
(en)
*
|
2021-04-26 |
2025-08-20 |
Grace Science Llc |
COMPOSITIONS AND METHODS FOR TREATING NGYL1 DEFICIENCY
|
|
EP4399314A4
(en)
*
|
2021-09-06 |
2025-09-10 |
Huidagene Therapeutics Singapore Pte Ltd |
TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2023093905A1
(zh)
|
2021-11-29 |
2023-06-01 |
上海瑞宏迪医药有限公司 |
Aadc、gdnf多核苷酸及其用于治疗帕金森病
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4499154A1
(en)
*
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
CN119487188A
(zh)
*
|
2022-04-19 |
2025-02-18 |
上海天泽云泰生物医药有限公司 |
用于治疗神经退行性障碍的重组aav载体
|
|
US20250171778A1
(en)
*
|
2022-04-25 |
2025-05-29 |
Myrtelle Inc. |
Treatments of Disorders of Myelin
|
|
AU2023260469A1
(en)
|
2022-04-25 |
2024-11-14 |
Cell Cure Neurosciences, Ltd. |
Methods and compositions for treating vision loss
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2024008950A1
(en)
|
2022-07-08 |
2024-01-11 |
Ospedale San Raffaele S.R.L. |
Transgene cassettes
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
AU2023306319A1
(en)
*
|
2022-07-12 |
2025-02-13 |
The Research Institute At Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218311A1
(fr)
|
2023-04-21 |
2024-10-24 |
Pulsesight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
WO2025160452A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Methods for fus-based delivery of viral particles to the brain
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|